Method for assessing validity of cell therapy product

Abstract

A composition according to an embodiment includes a first population of transformed mammalian cells with a transforming growth factor beta (TGF-β), the first population having a TGF-β expression level of 0.65 ng/105 cells/24 hours or more, and a second population of mammalian cells which are not transformed with the transforming growth factor beta, the second population having an expression level of a thrombospondin 1 (TSP-1) expression level of 31 ng/105 cells/24 hours or more.

What is claimed is: 
     
         1 . A composition comprising:
 a first population of transformed mammalian cells with a transforming growth factor beta (TGF-β), the first population having a TGF-β expression level of not less than 0.65 ng/10 5  cells/24 hours; and   a second population of mammalian cells which are not transformed with the transforming growth factor beta.   
     
     
         2 . The composition of  claim 1 , wherein the first population of the transformed mammalian cells are inactivated cells in replication incompetent state. 
     
     
         3 . The composition of  claim 1 , wherein the number of the untransformed mammalian cells of the second population and the number of the transformed mammalian cells of the first population are mixed with a mixing ratio of 3:1. 
     
     
         4 . The composition of  claim 1 , wherein the first population has the TGF-β expression level of not less than 1 ng/10 5  cells/24 hours. 
     
     
         5 . The composition of  claim 1 , wherein the first population has the TGF-β expression level of not less than 1.7 ng/10 5  cells/24 hours. 
     
     
         6 . The composition of  claim 1 , wherein the second population express thrombospondin 1 (TSP-1). 
     
     
         7 . The composition of  claim 1 , wherein the second population has the thrombospondin 1 (TSP-1) expression level of not less than 31 ng/10 5  cells/24 hours. 
     
     
         8 . The composition of  claim 1 , wherein the second population has the thrombospondin 1 (TSP-1) expression level of not less than 50 ng/10 5  cells/24 hours. 
     
     
         9 . The composition of  claim 1 , wherein the second population has the thrombospondin 1 (TSP-1) expression level of not less than 90 ng/10 5  cells/24 hours. 
     
     
         10 . An osteoarthritis therapeutic agent comprising the composition according to  claim 1 .